^
    9ms
    AB122 Platform Study (clinicaltrials.gov)
    P1, N=715, Recruiting, Taiho Pharmaceutical Co., Ltd. | N=367 --> 715 | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2024 --> May 2026
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation
    |
    Avastin (bevacizumab) • Cyramza (ramucirumab) • Lytgobi (futibatinib) • Yutuo (zimberelimab) • Lonsurf (trifluridine/tipiracil) • Jeselhy (pimitespib) • pamufetinib (TAS-115)
    over1year
    Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy. (PubMed, Sci Rep)
    The combination treatment further increased the percentage of GzmbCD8 T cells and decreased the percentage of macrophages compared with either treatment alone. These results highlight the potential therapeutic effect of TAS-115 in combination with PD-1 blockade, mediated via activation of antitumor immunity by TAS-115.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • IL2 (Interleukin 2) • CSF1R (Colony stimulating factor 1 receptor) • GZMB (Granzyme B)
    |
    pamufetinib (TAS-115)
    over2years
    AB122 Platform Study (clinicaltrials.gov)
    P1, N=292, Recruiting, Taiho Pharmaceutical Co., Ltd. | N=180 --> 292
    Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • BRAF mutation • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • KRAS overexpression • ALK-ROS1 fusion • NTRK fusion
    |
    Lytgobi (futibatinib) • Yutuo (zimberelimab) • Jeselhy (pimitespib) • pamufetinib (TAS-115)
    3years
    A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases. (PubMed, Clin Genitourin Cancer)
    TAS-115 appears to demonstrate anti-tumor activity and acceptable tolerability in CRPC patients with bone metastases.
    Clinical • P2 data • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • CSF1R (Colony stimulating factor 1 receptor)
    |
    docetaxel • abiraterone acetate • prednisone • pamufetinib (TAS-115)
    over4years
    [VIRTUAL] The multi tyrosine kinase inhibitor TAS-115 promotes innate and adaptive immune responses of androgen deprivation therapy in mouse prostate cancer (AACR-II 2020)
    We also use phenotyping, gene expression and immunohistochemical studies to show that reducing immunosuppressive immune cells led to increased CD8 T cell recruitment and activation. These findings provide evidence to support that TAS-115 sequenced with ADT has the potential to augment innate and adaptive antitumor immunity in prostate cancer.
    Preclinical
    |
    TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • PTEN (Phosphatase and tensin homolog) • CD163 (CD163 Molecule) • IL10 (Interleukin 10) • CSF1R (Colony stimulating factor 1 receptor) • ITGAM (Integrin, alpha M)
    |
    pamufetinib (TAS-115)
    over4years
    TAS-115 inhibits PDGFRα/AXL/FLT-3 signaling and suppresses lung metastasis of osteosarcoma. (PubMed, FEBS Open Bio)
    We also show that these signaling pathways are activated in various human osteosarcoma cell lines and are involved in proliferation. Our results suggest that TAS-115 may have potential for development into a novel treatment for metastatic osteosarcoma.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    pamufetinib (TAS-115)